Insider Transactions in Q1 2021 at Agios Pharmaceuticals, Inc. (AGIO)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
500
-4.48%
|
$24,000
$48.58 P/Share
|
|
Mar 01
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,200
-16.45%
|
$103,400
$47.99 P/Share
|
|
Feb 24
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
986
-6.01%
|
-
|
|
Feb 22
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+16.9%
|
-
|
|
Feb 22
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
199
-9.98%
|
-
|
|
Feb 22
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
692
+25.76%
|
-
|
|
Feb 22
2021
|
David P Schenkein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
821
-0.72%
|
-
|
|
Feb 22
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,774
+2.39%
|
-
|
|
Feb 22
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-1.62%
|
-
|
|
Feb 22
2021
|
Darrin Miles Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
725
+5.18%
|
-
|
|
Feb 16
2021
|
David P Schenkein Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,540
-2.24%
|
-
|
|
Feb 16
2021
|
David P Schenkein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,125
+6.7%
|
-
|
|
Feb 16
2021
|
Carman Alenson Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
561
-30.11%
|
-
|
|
Feb 16
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
790
+29.78%
|
-
|
|
Feb 16
2021
|
Christopher Bowden Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,069
-13.67%
|
-
|
|
Feb 16
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,750
+15.38%
|
-
|
|
Feb 16
2021
|
Darrin Miles Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,916
-18.86%
|
-
|
|
Feb 16
2021
|
Darrin Miles Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
922
+5.63%
|
-
|
|
Feb 14
2021
|
Carman Alenson Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
889
+45.31%
|
-
|
|
Feb 14
2021
|
Jacqualyn A Fouse Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,398
-5.5%
|
-
|
|
Feb 14
2021
|
Jacqualyn A Fouse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,333
+15.5%
|
-
|
|
Feb 14
2021
|
Christopher Bowden Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+24.42%
|
-
|
|
Feb 14
2021
|
Darrin Miles Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,666
+37.34%
|
-
|
|
Feb 04
2021
|
John Maraganore Director |
SELL
Bona fide gift
|
Direct |
3,415
-11.32%
|
-
|
|
Jan 06
2021
|
Bruce Car Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,191
-14.38%
|
$52,404
$44.09 P/Share
|
|
Jan 06
2021
|
Bruce Car Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,437
+29.32%
|
-
|